Scientific evidence supporting recommendations on the use of the 9-valent HPV vaccine in a 2-dose vaccine schedule in Australia

Wnukowski-Mtonga, Peter; Jayasinghe, Sanjay; Chiu, Clayton; Macartney, Kristine; Brotherton, Julia; Donovan, Basil; Hall, Madeline; Smith, David W.; Peterson, Karen; Campbell‐Lloyd, Sue; Selvey, Christine; Giles, Michelle; Kaldor, John; Marshall, Helen

doi:10.33321/cdi.2020.44.33

Cited by 9 publications

(8 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cervarix, despite having a slightly narrower range of protection, is arguably the most a cost‐effective treatment that best suited to low‐income countries 19 . In addition to preventing 90% of high‐risk HPV infections, the tetravalent vaccine also prevented 90% of condyloma acuminatum, 20 and Gardasil 9 valent vaccine was a particle vaccine, 21 which could prevent an additional 15% of cervical cancer and up to 20% of other cervical cancer HPV‐related cancers 22 . In general, the 9‐valent vaccine offers the broadest protection, while the bivalent vaccine offers the best value for money.…”

Section: Discussionmentioning

confidence: 99%

Challenges of hesitancy in human papillomavirus vaccination: Bibliometric and visual analysis

Deng

Shen

et al. 2023

Health Planning & Management

View full text Add to dashboard Cite

BackgroundHuman papillomavirus (HPV) vaccine has immense research value in the prevention of related tumours. A huge body of work has been published in this field, which may pose difficulties for researchers aiming to investigate all the available information. However, bibliometrics can provide deep insights into this research field.ObjectiveWe aimed to study HPV vaccine development, visually analyse the development status, trends, research hotspots, and frontiers of this field, and provide a reference for research on it.MethodsArticles were acquired from the Web of Science Core Collection. VOS viewer and CiteSpace software were used to analyse publication growth, country/region, institution, journal distribution, author, reference, and keywords, and collected burst keyword words to display research hotspots.ResultsA total of 4831 references were obtained, and the annual number of publications increased fluctuating over the past decade. The United States of America ranked at the top in terms of percentage of articles. The institution with the highest number of research publications in this field was the Centers for Disease Control and Prevention. The most productive and frequently cited authors was Lauri E Markowitz. The journal with the most publications in this field was Vaccine, and the most influential journal was Paediatrics. The most frequently cited reference was ‘A 9‐Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women’. Burst detection analysis of top keywords showed that ‘national immunisation survey’, ‘social media’, and ‘hesitancy’ are the current research frontiers in this field.ConclusionThis study provides useful information for acquiring knowledge on HPV vaccine. Research on solving the hesitation of HPV vaccination will become an academic trend in this field, which can offer guidance for more extensive and in‐depth studies in the future.

show abstract

Section: Discussionmentioning

confidence: 99%

Challenges of hesitancy in human papillomavirus vaccination: Bibliometric and visual analysis

Deng

Shen

et al. 2023

Health Planning & Management

View full text Add to dashboard Cite

show abstract

“…Those who started vaccination after 15 years should receive 3 doses, with an interval of 2 and 6 months after the first application, respectively. In 2018, the country replaced the 4-valent vaccine with the 9-valent vaccine, including being used to finalize the scheme if it had been started with the tetravalent [21]. • Referenced country: Canada.…”

Section: -Valentmentioning

confidence: 99%

HPV Vaccine: Integrative Review of National and International Guidelines

Filho¹,

Rocha²,

Bacha³

et al. 2022

Health

View full text Add to dashboard Cite

HPV (Human Papillomavirus) is an adenovirus of the Papillomaviridae family with approximately 200 subtypes (subdivided into low and high oncogenic risk groups), responsible for almost 99% of cervical cancers. Worldwide, there are more than 570,000 new cases and more than 311,000 women die each year from cervical cancer; for Brazil, the estimate is of more than 16,000 new cases per year. It is known that cervical cancer is one of the most easily preventable forms of cancer, as there is a highly effective vaccine against HPV. However, the morbidity and mortality rates correlated with human papillomavirus are still concerning, especially in less developed countries. In 2020, the WHO (World Health Organization) presented three goals to achieve by 2030 the worldwide extermination of cervical cancer; among these goals is vaccination. Is the world preparing for this battle? The present work is an integrative review, comparing national and international guidelines for HPV vaccination published in the last five years in the consulted databases, using the descriptors "cervical cancer", "prevention" and "guideline" and the boolean operator "and", from which nine articles were selected. The study made it possible to compare international and national guidelines for vaccination against HPV, showing that developed countries implemented the HPV vaccine longer ago and follow the WHO recommendations more rigorously and effectively than underdeveloped or developing countries. Adopting a single dose as a strategy, as suggested by the WHO in April 2022, could be an important step towards increasing coverage and providing protection for a greater number of girls who do not have access to HPV immunization.

show abstract

“…They reported that one and two doses of the HPV-16/18 were as protective as three doses in women after 4 years follow-up. Finally, the Australian Technical Advisory Group on Immunization reported a non-inferior antibody responses after two doses given at 6 and 12 months in girls and boys aged 9-14 years compared to women (16-26 years) after three doses supporting the 2-dose schedule for adolescents of this age group [32]. A randomized, observational trial evaluating alternative nHPV vaccination schedules in young females in West Africa is still ongoing (NCT03832049).…”

Section: Efficacymentioning

confidence: 99%

From the Infection to the Immunotherapy in Cervical Cancer: Can We Stop the Natural Course of the Disease?

et al. 2020

View full text Add to dashboard Cite

Cervical cancer (CC) is the second leading cause of cancer death in women aged 20–39 years. Persistent infection with oncogenic types of human papillomavirus (HPV) represents the most important risk factor for the development of cervical cancer. Three HPVs vaccines are currently on the global market: bivalent, quadrivalent, and nonavalent. The nonavalent vaccine provides protection against almost 90% of HPV-related CC. Despite availability of primary and secondary prevention measures, CC persists as one of the most common cancers among women around the world. Although CC is a largely preventable disease, management of persistent or recurrent CC no longer amenable to control with surgery or radiation therapy has not improved significantly with the progress of modern chemotherapy and disseminated carcinoma of the cervix remains a discouraging clinical entity with a 1-year survival rate between 10% and 15%. Over the last few years, there has been increasing interest in immunotherapy as a strategy to fight tumors. This article focuses on recent discoveries about the HPV vaccine and immunotherapies in the prevention and treatment of CC, highlighting the future view.

show abstract

Scientific evidence supporting recommendations on the use of the 9-valent HPV vaccine in a 2-dose vaccine schedule in Australia

Cited by 9 publications

References 41 publications

Challenges of hesitancy in human papillomavirus vaccination: Bibliometric and visual analysis

Challenges of hesitancy in human papillomavirus vaccination: Bibliometric and visual analysis

HPV Vaccine: Integrative Review of National and International Guidelines

From the Infection to the Immunotherapy in Cervical Cancer: Can We Stop the Natural Course of the Disease?

Contact Info

Product

Resources

About